Nodding to bloggers, Lilly digitizes content

Share this article:
Nodding to bloggers, Lilly digitizes content
Nodding to bloggers, Lilly digitizes content

Lilly and Disney said that their custom books for children and families with type 1 diabetes—previously distributed only through doctor's offices—are now available online.

Partners since 2011, Disney Publishing Worldwide and Lilly Diabetes created special materials for type 1 families, including a series of custom books for children of various ages and stages, and an online hub on Disney's, later changed to Earlier this year, the partners decided to expand the books internationally.

Their latest move, to digitize the content, was spurred by a meeting with the online diabetes community last May, a spokesperson told MM&M. At the meeting, parents of patients with type 1 diabetes gave the company feedback on the books.

That is, while free, the books had previously only been distributed through pediatric endocrinologists' offices. Many caregivers, bloggers said, access treatment through a pediatrician or adult primary care doctor.

The books, which cover real-life issues like participating in sporting activities and attending social events, feature one with the Disney character Coco, a monkey with type 1 diabetes, and two stories from Disney's ESPN brand aimed at tweens.

For young readers, Coco and Goofy's Goofy Day follows the exploits of Coco with Mickey Mouse and friends. A read-along audio version of the book is also available online.

All of the online versions are accessible at the site and are viewable on desktop or tablet, featuring responsive design for uniform viewing across devices, Lilly and Disney stated in an announcement earlier this month, adding that more digital books will be made available in coming months. contains articles, videos and advice from caregivers, including two mothers raising children with type 1 diabetes, and is updated monthly.

Type 1 diabetes affects more than 13,000 young people in the US each year, Lilly said.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...